Hofseth BioCare ASA · OSL:HBC
Hofseth BioCare ASA — Investor Presentation (November 2020)
56 slides from Hofseth BioCare ASA's investor presentation, Nov 11, 2020
Slide 1: Hofseth BioCare business presentation
Hofseth BioCare business presentation Presenter: Date: Place: HBC 11.11.2020 Online
Slide 2: Fresh, unprocessed products: oil, protein, calcium, pet feed
Fresh, unprocessed Only protein hydrolysate with Natural source of calcium Pet feed Unrefined NO bitterness; enabling better uptake to bone & Natural fish oil High bioavailability (98%) collagen II, trace elements and Full spectrum of omegas Benefits beyond nutrition natural bone growth factors Low
Slide 3: Proprietary enzymatic hydrolysis process protected by patents and trade secrets
Proprietary enzymatic hydrolysis process protected by patents and trade secrets now covering the processing of all marine sources of off-cuts Sales mix moving away from low margin animal feed towards high margin human grade products Diversified R&D pipeline focussed on treatment of anemia, inflammat
Slide 4: Hofseth International and processing facilities
• Annual harvest volume of • Three processing facilities with • Using off-cuts from the around 10-12,000 tons a total capacity of 100,000 tons processing division to produce salmon/trout • Global customer base (Costco. high value products for pets & • No GMO, no antibiotics Lidl, Aldi, Coles) humans
Slide 5: Whole fish, no waste, non-GMO, no antibiotics
4°C WHOLE FISH, NO Under utilized by-products “waste” or off-cuts WASTE, NON-GMO, SALMON OIL OMEGO® NO ANTIBIOTICS 33% Currently, 20.000 MT of raw materials arrive per year at Hofseth BioCare’s plant within hours after production. 100% SALMON PROTEIN PROGO® Raw Enzymes Water material Our patented en
Slide 6: Certifications and approvals
• FSSC 22000 certified • GMP+ certified • Friend of the Sea certified • Kosher certified • Approved establishment by Norwegian Food Safety Authority • FDA-approval • Halal certification possible on request
Slide 7: Full spectre of omega fatty acids
Full spectre of omega fatty acids Product name: Fat content: Lipo-peptides: FFA: OmeGo® More than 99.1 % Less than 0.9 % Less than 1 %
Slide 8: Unrefined, fresh natural Norwegian salmon oil
• Unrefined, fresh Natural Norwegian Salmon Oil, so… • …it contains all the fish omegas, not just 18/12, providing all the benefits of fresh fish • …it’s anti-inflammatory with low totox levels, no added antioxidants & 4 years shelf life • …it has broad benefits on blood lipids & cardiovascular heal
Slide 9: Gentle oil extraction process versus conventional processing
3. No Acid Added 4. 18/12 oils & Omega-3 Extraction › During processing acid commonly added to de-esterify the fats in the oil to free fatty acids › Requires a distillation column to extract the 18/12 FFAs (FFAs), a process that damages the › Alcohol is used to re-esterify the 18/12 fraction making
Slide 10: Omego provides full spectre of omega-3s
Omego provides full spectre of omega-3s (including DPA) and all other PUFAs contained in fresh fish: • contains DHA/EPA at 75mg/1000mg, the NOTE 18/12 oil contains same level as in whole fish 300mg/1000mg DHA & EPA but only 50% is absorbed as in • contains all 13 omegas including DHA, unnatural ethy
Slide 11: Healthy human reduction in serum oxLDL
Healthy human reduction in serum oxLDL oxLDL-GP Starting Value U/ml oxLDL-GP Final Value U/ml 2,9 • Full spectrum of Omega-3s (DHA, EPA, DPA) 2,8 providing all the benefit of fresh fish including anti-inflammatory & antioxidant benefits. No added antioxidant, stable, natural product 2,7 with 4 years
Slide 12: Low oxidation / Totox levels
Fresh, minimal processing = OmeGo has very low oxidation / Totox (aka rancidity) levels: • Low TOTOX levels are essential to maximise the health benefits of fish oil; • The time to extract the oil and the quality of manufacturing is key; • Natural antioxidant astaxanthin = no need to add vitamin E -
Slide 13: R&D identifying differentiated health benefits (eosinophil modulation)
HBC’s R&D work continues to identify medically important & differentiated health benefits: HBC has identified a minor lipid-soluble non-PUFA element that modulates eosinophil effector function (EEF) invitro and in animal models of eosinophilic inflammation (patent pending). Eosinophils are a white b
Slide 14: Eosinophilic asthma and asthma market
7-8% population suffers asthma with up to 40% driven by eosinophils Eosinophilic asthma typically requires higher doses of steroids & increased risks of side effects including osteoporosis, weight gain, hypertension, diabetes, cataracts. Less likely to have good asthma control with increased risk of
Slide 15: Process description versus other oils
Process description Other salmon oils Anchovies oils Concentrated fish oils No pressure cooking and high physical stress on the biomass to extract the oil No bleaching (caustic) No winterization No acid hydrolysis to FFA No high temperature fraction distillation to concentrate EPA- DHA No re-esterif
Slide 16: Brilliant Salmon Oil available at Costco
~ BRILLIANT 2 == SALMON OIL as Zz 5 BRILLIANT A N OIL} one Pen y aL a fy eect ma cor Brilliant Salmon Oil is now available at Costco stores across the UK, Spain, Iceland and in over 1,000 retail stores in the US HBC
Slide 17: 98% pure protein
98 % pure protein Product name: Protein content: Fat content: Ash content: ProGo® More than 97 % Less than 0.5 % Less than 2.5 %
Slide 18: Pure salmon protein hydrolysate
Pure Salmon Protein Hydrolysate 98% protein, fat content less than 0.5%, ash content less than 2.5% Enzymatic hydrolysis to peptides and amino acids eases GI absorption Antioxidant and anti-inflammatory effects demonstrated in trial work Broad utility from post-exercise recovery to recovery from a b
Slide 19: Proprietary patented technology delivering bioactive peptides
Protein HBC’s proprietary patented technology delivering easily Aminoacid absorbed bioactive peptides & amino acids from HBC’s proprietary tailored enzyme technology Endopeptidase Exopeptidase BMI Hemoglobin Energy
Slide 20: Bioaccessibility and digestion benefits
Bioaccesibility • Fastest uptake of nitrogen into the body • Highly soluble in water due to low molecular size • More than 98% digestibility, and rapid digestion time Digestion times • Proven ability to increase red blood cells in anemic individuals • Proven ability to reduce BMI • Hypo allergenic
Slide 21: Change in hemoglobin and serum ferritin
Change in hemoglobin & serum ferritin after 6 weeks of treatment Change in hemoglobin (Hb, g/dl) Change in ferritin (ng/ml) 12 60 16g once a day of bioactive peptides 140% produced normal ferritin levels & near 15% 11,5 50 normal levels of Hb after 6 weeks’ Plasma ferritin level (ng/dl) treatment. P
Slide 22: Health Canada claims and iron deficiency anemia market
Qualified Health Claims (QHC) approved by Health Canada October 2020 for: “the maintenance of healthy levels of ferritin and hemoglobin”, “helps maintain healthy levels of blood components required for oxygen transport” & “provides antioxidants for the maintenance of good health”. This is a unique c
Slide 23: Stick pack format for convenient dosing
Stick pack format for convenient dosing
Slide 24: Change in BMI after weeks of treatment
Change in BMI after 6 weeks of treatment ProGo™ WPI 8,0% • Obesity is a major global health problem with 6,0% over 3 million adults dying each year from 4,0% obesity related complications 2,0% 1,6% • 16 g / day ProGo™ treatment for 6 weeks showed a 5.9% decrease in Body Mass Index 0,0% (baseline BMI
Slide 25: Impact on BMI-related serum biomarkers
Impact on BMI-related serum biomarkers after 6 weeks of treatment 70,0% 63,2% • Adiponectin (Adipo) 60,0% • plasma protein derived from adipose tissue with anti- 50,0% atherogenic and insulin-sensitizing activities • low adipo levels are closely associated with the metabolic 40,0% syndrome, obesity
Slide 26: Overweight and obesity market
• Over two thirds of the US population is overweight (BMI 25+) or obese (BMI 30+) i.e. >200M • Overweight / obesity results in an inflammatory state with increased inflammatory cytokines • Moderate weight loss (>5%) has clear health benefits including reducing the risk of • Diabetes • Cardiovascular
Slide 27: Change in energy and vitality
Change in energy and vitality after just 2 weeks of treatment 16 14 14 • 21 out of 24 subjects showed a 90% 12 confidence level statistically significant Serum concentration increase in energy and vitality scoring from 10 Low 10 Day 1 baseline results at the end of the 4 Low to Moderate 8 8 8 Modera
Slide 28: Collagen product
• > 25 % collagen • Collagen Type I from skin tissue • Collagen might contribute to • Reduce signs of aging • Faster healing of wounds • Anti-inflammatory effect • Increase mineral density in bones • Improved skin • Improved nails • Improved hair
Slide 29: Type I and III collagen with bioactive peptides
• Bringing the structural benefits of type I & III collagen and the bioactive antioxidant effects of the peptide mix • 18-week study in healthy adults showed* • Increase in energy levels • Improvement in hair, nails & skin quality • Reduction in oxidative stress / free radical activity (ROS/RNS) via
Slide 30: Natural marine calcium
Natural marine calcium Product name: Elemental calcium: Elemental phosphorus: Collagen: CalGo® More than 17 % More than 8 % More then 24 %
Slide 31: CalGo for joint and bone health
Highly bioactive with potential to enhance joint and bone health • No additives • Rich in Type II Collagen, 24% by weight • Microcrystalline hydroxyapatite form of calcium • Natural source of phosphorus • Clinical trial work in joint health and osteoporosis to commence in 2020 CalGo ® contains the k
Slide 32: CalGo effect on femur (rat model)
CalGo™ effect on femur after 8 weeks (rat model) Femur Cortical Thickness (mm) • Increased cortical thickness (strength) by Femur Bone Mineral Density (mg/cm2) 33%* & bone mineral density / BMD by 9% vs placebo (no calcium added)* 0,80 245 240 • The cortical thickness increase was almost double the
Slide 33: HBC brand launched in Norway
• HBC brand launched in Norway • Logistics & website in-place • Initial uptake very favourable – strong traction with primary care physicians
Slide 34: Skeletal health market
Osteoarthritis affects 40%+ of over 65’s Ageing population & obesity resulting in rising prevalence Osteoporosis typically seen in post-menopausal women with >2M osteoporotic fractures pa in US alone Skeletal health market Calcium supplementation: - Multi-billion $ market led by calcium carbonate de
Slide 35: Yield and revenue sensitivities: product overview
Yield & Revenue Sensitivities SALMON OIL SALMON PROTEIN SALMON CALCIUM PHP OMEGO® PROGO® CALGO® PETGO™ @ HBC
Slide 36: Processing volumes, yields and pricing by ingredient
• Current processing volumes 20,000 MT pa, at Midsund Plant • New spray drying facility at Midsund will improve both product yield and quality: completion Q4 2020 INGREDIENT YIELD VOLUME (MT) B2B PRICE B2C MEDICAL NUTRITION 2021 Asthma, COVID, CVD 20.5% 4000 - 200+ pricing tbc - 60 Anaemia, IBD 5% 1
Slide 37: Norway facilities and capacity expansion
50.000 MT capacity Berkåk – 2,500 MT of protein Rørvik Turning our second factory into a hydrolysis plant 25.000 MT capacity today – 1,250 MT of protein Norway $10.000.000 investment > Total market of salmon in Norway is 1.3 million Trondheim MT, of which Hofseth processes 60.000 MT > 430,000 MT of
Slide 38: Fish protein hydrolysate production forecasts
World, Europe and Hofseth BioCare production forecasts Total European Fish Protein Hydrolysates Market of 24,825 (Kilo Tons) in 2019 Actual production 2019 Estimates 2025 Codfish Others Anchovy Anchovy 1,709 0,965 3,681 4,984 Molluscs 7% 4% 15 % 13 % 1,091 Crustacean4 % 0,573 2% Tilapia 5,814 Tilapi
Slide 39: Atlantic Sapphire joint venture in Miami
• November 1st 2019 announced the signing of a Letter of Intent to establish a joint venture in Miami, Florida, USA. • The intention of the JV is to build and operate a facility in Miami, FL to produce valuable by-products from salmon off-cuts supplied by Atlantic Sapphire. • HBC’s proprietary intel
Slide 40: An emerging biotechnology company
AN EMERGING BIOTECHNOLOGY COMPANY
Slide 41: R&D development stages
DISCOVERY PRE-CLINICAL CLINICAL REGULATORY APPROVAL (Animal models) (Human) (Label claims) Literature Proof of Concept Randomized trial Health Canada Invitro Placebo Double Blind FDA PK/PD IP Safety Multicenter EFSA Dose range Th consistent high grade, natural raw material Leveraging academic collab
Slide 42: R&D pipeline by indication
DISCOVERY PRE-CLINICAL CLINICAL REGULATORY APPROVAL (Animal models) (Human) (Label claims) Prostate / ProGo NEC-IBD / ProGo OA / CalGo BMI / ProGo Anemia / ProGo AMD / OmeGo Literature Proof of Concept Randomized trial Health Canada Invitro Placebo Double Blind FDA CFS / ProGo PK/PD Acne / OmeGo EFS
Slide 43: Focus on anti-inflammatory and antioxidant benefits
FOCUS ON ANTI-INFLAMMATORY & ANTIOXIDANT BENEFITS OmeGo® ProGo® CollaGo® CalGo® • Key to health & healthy ageing • From healthy subjects to chronic diseases the body is trying to balance inflammation • Preventative health through to the targeted treatment of chronic disease • Leading potential indic
Slide 44: Product pipeline by fraction and indication
Product Product Fraction IP Discovery (~1y) Pre-Clinical (~2y) Clinical (~2-3y) Regulatory approval (~1-2y) Salmon SPH-FTH1 Iron Deficiency Anemia Treatment Health Canada (QHC approved) FDA S/F claim Protein Hydrolysate SPH-CollaGo Skin Health & provision Antioxidant benefits Health Canada (QHC appr
Slide 45: Target indications for ProGo, OmeGo and CalGo
Salmon Peptide Hydrolysate, ProGo ® Salmonid oil, OmeGo ® Reducing gastrointestinal (GI) COVID-19 anti-inflammatory co- inflammation: necrotizing enterocolitis & therapy ulcerative colitis Increasing hemoglobin and reducing Eosinophilic Asthma co-treatment iron deficiency anemia oxLDL-GP reduction f
Slide 46: Stanford GI research collaboration
• Our preclinical GI research • Oxidative stress is a common collaboration with Stanford University mechanism for many diseases continues in: associated with the GI tract. • necrotising enterocolitis (NEC) & • ProGo ® up-regulates protective • ulcerative colitis (UC) antioxidative systems and lowers
Slide 47: Ulcerative colitis market
Chronic inflammation of the colon with diarrhoea, pain, fever, weight loss >1mn patients in US & EU5 with onset in 20’s & 30’s Treatment advances have been focused on injectable, biologic therapies for severe UC Unmet need = control symptoms & limit long-term side effects in mild to moderately sever
Slide 48: Necrotizing enterocolitis background
• Prevalence of ca 7% in infants with a birthweight of 500-1500g & risk increases with diminishing birth weight. • Significant morbidity and mortality: 10%-50% in infants weighing less than 1500g. • No improvements in outcome in recent years but the understanding of the underlying process has greatl
Slide 49: Stanford collaboration NEC animal model
• Our collaboration with Stanford University has assessed the bioactive peptides in ProGo ® in an animal model of NEC. • Tissue injury was assessed biochemically & compared between ProGo-pretreated mice and their controls. • The results are very exciting: a protective effect of ProGo ® in neonatal m
Slide 50: Protective effect on GI tract in mouse NEC model
Protective effect on GI tract demonstrated with ProGo using a mouse model of NEC • Oxidative stress-induced gut injury with 0.3% hydrogen peroxide (H202) measured via keratin 8 (K8) fecal protein level • K8 is a structural protein within the epithelial lining of the gut and therefore a biochemical m
Slide 51: Weight gain in neonatal mice in NEC study
Weight gain in neonatal mice in NEC study • Control animals gained more weight compared to mice who received ProGo ® & H202 • This would suggest that the mechanisms of GI- protection by ProGo are unlikely nutritional, rather a bioactive effect • ProGo peptides upregulate a number of oxidative protec
Slide 52: Value creation: licensing and moving to human-grade products
Long-term goal to monetize the results of the R&D in the lab by licensing discoveries with large-cap pharma & biotech Proprietary Nutraceutical to Technology & Pharmaceutical Consumer & Pet Health Manufacturing Value Sales mix progressively moving JV & Licensing deals to utilize From patented docume
Slide 53: Links to studies
Study on digestion and bioavailability: http://www.hofsethbiocare.com/upload_images/E11E92222C3A42E9967E7A41EEDA2372.pdf Study on hemoglobin increase: http://www.hofsethbiocare.com/upload_images/5B82602E6CF04155960F1D9361B2CDF0.pdf Study on BMI reduction: http://www.hofsethbiocare.com/upload_images/
Slide 54: Investment summary
• Only sustainable, naturally manufactured salmonid oil, hydrolyzed protein and marine calcium • The only marine-based products from fish off-cuts with patented health benefits • Total barriers to entry via patent protection (on all marine species) & trade secrets • Scalability at low cost & via lic
Slide 55: Contact
Contact Dr. Crawford Currie Medical R&D & Investor Relations James Berger Head of Investor Relations & Strategy +41 79 950 10 34 +44 7968 195497 jb@hofsethbiocare.no cc@hofsethbiocare.no HBC
Slide 56: hofsethbiocare.com
This is different” hofsethbiocare.com & HBC’
Hofseth BioCare — Investor Presentation (November 2020) on 6ix